(0.07%) 5 525.50 points
(0.15%) 39 529 points
(0.02%) 19 932 points
(0.42%) $81.88
(-0.92%) $2.58
(-0.13%) $2 336.60
(0.95%) $29.52
(-1.11%) $1 002.80
(-0.44%) $0.929
(-0.45%) $10.63
(-0.20%) $0.789
(1.34%) $86.88
Live Chart Being Loaded With Signals
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives...
Stats | |
---|---|
आज की मात्रा | 246 505 |
औसत मात्रा | 1.51M |
बाजार मूल्य | 8.56M |
EPS | £-0.00250 ( Q2 | 2023-06-30 ) |
अगली कमाई की तारीख | ( £0 ) 2024-08-28 |
Last Dividend | £1.000 ( 2021-12-14 ) |
Next Dividend | £0 ( N/A ) |
P/E |
-2.06 (Sector) 0 (Industry) 0 |
ATR14 | £0.0560 (2.72%) |
ImmuPharma PLC सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध |
---|
10 सबसे अधिक नकारात्मक सहसंबंध |
---|
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
ImmuPharma PLC वित्तीय
Annual | 2023 |
राजस्व: | £0 |
सकल लाभ: | £-37 607.00 (0.00 %) |
EPS: | £-0.00810 |
FY | 2023 |
राजस्व: | £0 |
सकल लाभ: | £-37 607.00 (0.00 %) |
EPS: | £-0.00810 |
FY | 2022 |
राजस्व: | £0 |
सकल लाभ: | £-117 563 (0.00 %) |
EPS: | £-0.0126 |
FY | 2021 |
राजस्व: | £118 350 |
सकल लाभ: | £0.00 (0.00 %) |
EPS: | £-0.0325 |
Financial Reports:
No articles found.
ImmuPharma PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
First Dividend | £1.000 | 2021-12-14 |
Last Dividend | £1.000 | 2021-12-14 |
Next Dividend | £0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | £1.000 | -- |
Avg. Dividend % Per Year | 0.80% | -- |
Score | 0.33 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2021 | £1.000 | 8.00% |
2022 | £0 | 0.00% |
2023 | £0 | 0.00% |
2024 | £0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
14 Dec 2021 | £1.000 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
DNA2.L | Dividend Royal | 2024-04-18 | Quarterly | 9 | 16.51% | 8.69 |
FAIR.L | Dividend Royal | 2024-05-30 | Quarterly | 9 | 10.77% | 8.67 |
MPLS.L | Dividend Royal | 2024-04-11 | Quarterly | 7 | 12.84% | 8.67 |
BGLF.L | Dividend Royal | 2024-05-02 | Quarterly | 9 | 10.03% | 8.50 |
SEPL.L | Dividend Royal | 2024-05-30 | Quarterly | 11 | 10.34% | 8.34 |
DNA3.L | Dividend Royal | 2024-04-18 | Quarterly | 12 | 14.16% | 8.31 |
DEC.L | Dividend Royal | 2024-08-29 | Quarterly | 8 | 59.83% | 7.91 |
AA4.L | Dividend Royal | 2024-04-11 | Quarterly | 9 | 12.37% | 7.88 |
IMB.L | Dividend Royal | 2024-08-22 | Quarterly | 28 | 7.10% | 7.51 |
FBH.L | Dividend Royal | 2024-05-02 | Annually | 22 | 11.26% | 7.46 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -32.54 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.255 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -1.936 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0.807 | 0.800 | -0.967 | -0.773 | [1 - 3] |
quickRatioTTM | 0.125 | 0.800 | -3.97 | -3.18 | [0.8 - 2.5] |
cashRatioTTM | 0.125 | 1.500 | -0.416 | -0.623 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | -2.58 | 1.000 | -2.07 | -2.07 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.00502 | 2.00 | -0.00167 | -0.00334 | [0 - 30] |
freeCashFlowPerShareTTM | -0.00533 | 2.00 | -0.00267 | -0.00533 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | -0.326 | 1.000 | -8.76 | -8.76 | [0.2 - 0.8] |
operatingProfitMarginTTM | -31.51 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.0386 | 0.800 | -3.08 | -2.46 | [0.5 - 2] |
Total Score | -6.30 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -2.03 | 1.000 | -0.306 | 0 | [1 - 100] |
returnOnEquityTTM | -1.936 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.00533 | 2.00 | -0.00178 | -0.00533 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.00502 | 2.00 | -0.00167 | -0.00334 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.822 | 1.500 | -8.82 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -15.93 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -3.03 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
ImmuPharma PLC
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं